NASDAQ:SRRA - Sierra Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.87 -0.04 (-2.09 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.91
Today's Range$1.85 - $1.94
52-Week Range$1.05 - $3.70
Volume101,711 shs
Average Volume213,286 shs
Market Capitalization$139.26 million
P/E Ratio-2.49
Dividend YieldN/A
Beta1.8
Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRRA
Previous SymbolNASDAQ:DNAI
CUSIPN/A
Phone604-558-6536

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.27 per share

Profitability

Net Income$-53,330,000.00

Miscellaneous

EmployeesN/A
Market Cap$139.26 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

How were Sierra Oncology's earnings last quarter?

Sierra Oncology Inc (NASDAQ:SRRA) released its quarterly earnings results on Thursday, February, 28th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. View Sierra Oncology's Earnings History.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Sierra Oncology.

What is the consensus analysts' recommendation for Sierra Oncology?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sierra Oncology.

Has Sierra Oncology been receiving favorable news coverage?

News coverage about SRRA stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sierra Oncology earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Sierra Oncology's key competitors?

What other stocks do shareholders of Sierra Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sierra Oncology investors own include Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Global Blood Therapeutics (GBT), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Trevena (TRVN), Mallinckrodt (MNK), Viking Therapeutics (VKTX), ContraFect (CFRX) and TG Therapeutics (TGTX).

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the folowing people:
  • Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)
  • Dr. Barbara Klencke, Chief Devel. Officer (Age 62)
  • Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)
  • Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)
  • Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50)

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by many different of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (6.56%), Perceptive Advisors LLC (3.59%), Prosight Management LP (3.43%), 683 Capital Management LLC (2.92%), Dimensional Fund Advisors LP (1.36%) and Dimensional Fund Advisors LP (1.36%). View Institutional Ownership Trends for Sierra Oncology.

Which major investors are selling Sierra Oncology stock?

SRRA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sphera Funds Management LTD., Perceptive Advisors LLC, Orbimed Advisors LLC, Prosight Management LP, Algert Global LLC, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Sierra Oncology.

Which major investors are buying Sierra Oncology stock?

SRRA stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, 683 Capital Management LLC, Hikari Power Ltd and Acadian Asset Management LLC. View Insider Buying and Selling for Sierra Oncology.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $1.87.

How big of a company is Sierra Oncology?

Sierra Oncology has a market capitalization of $139.26 million. The biotechnology company earns $-53,330,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is http://www.sierraoncology.com.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150 -885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected]


MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: What is the S&P 500 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel